Pfizer Australia Pty Ltd

Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors or severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.

Litfulo (ritlecitinib) has been approved for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

The Comirnaty JN.1 vaccine (Bretovameran), adapted to the SARS-CoV-2 Omicron JN.1 strain, has been approved to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 6 months of age and older.

Elrexfio (elranatamab) was provisionally approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody and have demonstrated disease progression on the last therapy.

Paxlovid (nirmatrelvir and ritonavir) was approved for the treatment of coronavirus disease 2019 (COVID-19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.

Comirnaty Original/Omicron BA.4-5 Vaccine was provisionally approved for immunisation against coronavirus disease 2019 (COVID-19) caused by SARSCoV-2 in individuals 6 months of age or older.

Velsipity (etrasimod) was approved for the treatment of adults with moderately to severely active ulcerative colitis who have not benefited from prior therapies

Xeljanz (tofacitinib) was approved for the treatment of ankylosing spondylitis and for active polyarticular course juvenile idiopathic arthritis.

Cibinqo (abrocitinib) has been approved for the treatment of moderate-to-severe atopic dermatitis in adults.

Tukysa (tucatinib) has been approved to be used in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2 positive unresectable or metastatic colorectal cancer.